

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



香港金融集團

HONG KONG FINANCE INVESTMENT HOLDING GROUP LIMITED
香港金融投資控股集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 7)

APPOINTMENT OF CHIEF EXECUTIVE OFFICER

The board of directors (the “Board”) of Hong Kong Finance Investment Holding Group Limited (the “Company”) is pleased to announce that Dr. Lew Mon Hung has been appointed as the chief executive officer of the Company with effect from 25 March 2020.

Dr. Lew, aged 72, received a Doctoral Degree in Finance from Sabi University in France and an Honorary Doctoral Degree from Sinte Gleska University of California in the United States. He is a Datuk and Prince of Kingdom of Sulu (蘇祿王國拿督和親王) of the Philippines. Dr. Lew was a co-chairman and executive director of Wai Chun Group Holdings Limited (HK1013), the chairman and executive director of G-Resources Group Limited (stock code: 1051), the chairman and executive director of ABC Communications (Holdings) Limited (stock code: 0030), an executive director of Sino Union Petroleum & Chemical International Limited (0346) and the vice chairman and executive director of Pearl Oriental Oil Limited (stock code: 0632), all being companies listed in Hong Kong.

Dr. Lew Mon Hung served as a member of the 11th Chinese People's Political Consultative Conference, a member of the Foreign Affairs Committee, a member of the Commission on Strategic Development of the Hong Kong SAR, a part-time consultant to the Central Policy Unit of the Hong Kong SAR Government, the chairman of the 100 Strategic Think Tanks (百家戰略智庫), the chief consultant of Core Pacific – Yamaichi International (H.K.) Limited and a director of Mirror Post Cultural Enterprises Company Limited.

He joined the financial sector of Hong Kong in the 1970s and served as sales representative, manager, general manager, president, chief consultant, executive director, vice chairman and chairman of various financial institutions and listed companies over the years. He successively engaged in the brokerage business for Japanese futures, US gold futures, 99 gold, foreign exchange, securities, mergers and acquisitions by investment banks, and has over 50 years of extensive operation and management experience in financing, fund raising and mergers and acquisitions of listed companies.

Save as disclosed above, Dr. Lew (i) did not hold any position with the Company or its subsidiaries; (ii) does not have any relationship with any directors, senior management, management shareholders, substantial or controlling shareholders of the Company; (iii) does not have any interests in shares (as defined under Part XV of the Securities and Futures Ordinance) as at the date of this announcement.

Save as disclosed above, there is no other information in relation to the appointment of Dr. Lew that is required to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, and there is no other matter which needs to be brought to the attention of the shareholders of the Company.

The Board would like to extend its warm welcome to Dr. Lew on his appointment. It is believed that Dr. Lew's extensive experience in financing, fund raising and mergers and acquisitions of listed companies will play an active role on the business development and efficiency of the Group.

By Order of the Board
Hong Kong Finance Investment Holding Group Limited
Dr. Hui Chi Ming, G.B.S., J.P.
Chairman

Hong Kong, 25 March 2020

As at the date of this announcement, the Honorary Chairman and Senior Consultant of the Company is Dr. Yukio Hatoyama; the senior consultants of the Company comprise Dr. Wang Tao and Mr. Lalaharisaina Joelivalerien; the Board comprises eight executive Directors, namely, Dr. Hui Chi Ming, G.B.S., J.P., Mr. Neil Bush, Dr. Chui Say Hoe, Mr. Xu Jun Jia, Mr. Cao Yu, Mr. Ren Qian, Mr. Lam Kwok Hing, M.H., J.P. and Mr. Nam Kwok Lun; and four independent non-executive Directors, namely, Mr. Chan Tsang Mo, Mr. Ngan Kam Biu, Stanford, Mr. Tam Chak Chi and Mr. Ma Kin Ling.